Lv1
70 积分 2025-05-23 加入
Reprogramming the glycocalyx: Advances in glycoengineering for immunomodulation and regenerative medicine
1个月前
已完结
Association of short-chain fatty acids and the gut microbiome with type 2 diabetes: Evidence from the Henan Rural Cohort
1个月前
已完结
Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study
1个月前
已完结
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
3个月前
已完结
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
3个月前
已完结
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
3个月前
已完结
A general cardiovascular risk profile: The Framingham study
3个月前
已完结
Adding empagliflozin to ongoing metformin improves metabolic profile, tg-g and fib-4 indexes and liver function tests in type 2 diabetic patients with NAFLDS, a clinical trial
3个月前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
3个月前
已完结
Potent Covalent Irreversible Inhibitor of KRAS G12C IBI351 in Patients with Advanced Solid Tumors: First-In-Human Phase I Study
5个月前
已完结
皖公网安备34019202002308
